Pricing Tailwinds Surface, but Mission’s Wait Thesis Unchanged

What happened

A July 27 Zacks article highlights how improving avocado pricing and broader sourcing could lift Mission Produce's margins as supply-demand normalizes, and notes the Calavo deal as a catalyst. However, our master report already assumed stable per-unit margins and disciplined execution—the news simply confirms existing assumptions rather than providing new evidence of outperformance. At $13.17, the stock trades at ~8.3x EBITDA and 25x earnings, embedding mid-single-digit volume growth and synergy delivery, leaving little room for error. Persistent tariff risks, high customer concentration, and heavy capex continue to limit free cash flow conversion and upside. Until the Calavo deal closes with regulatory clearance and demonstrated cost synergies, the current valuation offers insufficient margin of safety for new capital.

Implication

Near-term margin relief from better pricing and sourcing is incremental and already reflected in consensus estimates. The Calavo deal’s promised $25 million in synergies hinges on regulatory clearance and operational execution, both of which carry significant uncertainty. At $13.17, the stock’s 8.3x EBITDA multiple embeds a base-case scenario that leaves minimal cushion against tariff shocks, integration missteps, or softening demand. With a base-case intrinsic value of $15 and a bear case near $10, the risk-reward is skewed. We believe investors are better served waiting for a pullback to $11 (≈6.5–7x EBITDA) or concrete synergy proof before adding exposure.

Thesis delta

The article highlights near-term margin support, but this is consistent with our base assumptions. The core wait thesis remains intact: the stock already prices in steady margins and Calavo synergies, while tariff and execution risks are underappreciated.